A Birmingham company is working with Cepheid to develop a PCR test for monkeypox, a virus that has spread to the U.S., though the CDC classifies the threat as low. Birmingham-based BioGX is ...

Though the global number of recorded monkeypox cases continues to climb—passing 4,100 last week, according to the Centers for Disease Control and Prevention (CDC)—many researchers and epidemiologists ...

SUNNYVALE, Calif., Jan. 18, 2024 /PRNewswire/ -- Cepheid announced today that it has received FDA Clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert® Xpress MVP. This ...

Cepheid has announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert™ MRSA test, which runs on the GeneXpert® System, for the detection of ...

US firm Cepheid is in the process of seeking approvals to manufacture point-of-care Covid-19 RT-PCR diagnostic cartridges that will be made in India. "From India's perspective, and manufacturing ...

Cepheid received an STTR grant of $3.3 million from NIAID for development of sample processing cartridges for rapid PCR TB detection. “Cepheid has developed a PCR cartridge that detects the presence ...

Companies have paid-up licenses to make and sell the respective lines of products. Cepheid and Idaho Technology have agreed to resolve a dispute related to their intellectual property, through a ...

The US Food & Drug Administration (FDA) granted Emergency Use Authorization (EUA) to Cepheid in September 2021 for its PCRplus-based Xpert CoV-2/Flu/RSV plus multiplex test for the viruses that cause ...

DUBLIN--(BUSINESS WIRE)--The "Real-time PCR (qPCR) andDigital PCR (dPCR) Market Analysis by Technology, by Product (Consumables & Reagents, Instruments, Software & Services), by Application and ...

Cepheid’s CPHD rapid influenza and RSV assay – the Xpert Flu+RSV Xpress test – recently won the U.S. FDA 510(k) marketing approval and the Clinical Laboratory Improvement Achievements (CLIA) waiver.